Buroker T, Wojtaszak B, Dindogru A, DeMattia M, Baker L, Groth C, Vaitkevicius V K
Cancer Treat Rep. 1978 May;62(5):689-92.
In an attempt to substitute ftorafur for burdensome 5-fluorouracil (5-FU) infusions, 52 previously untreated patients were randomized to receive ftorafur with either mitomycin C or methyl-CCNU. Ftorafur was administered monthly as a 2-hour infusion daily x 5 days. Mitomycin C and methyl-CCNU were repeated every 8 weeks. A response rate of 27% (seven responses among 26 patients) was demonstrated on the mitomycin C arm compared to a response rate of 15% (four responses among 26 patients) on the methyl-CCNU arm (P = 0.25). There was no significant difference in the median survival between treatment arms. Central nervous system toxicity occurred in greater than 30% of the patients and appeared to be the limiting factor with ftorafur administration. Alternate schedules of ftorafur should be explored since there appears to be little advantage of a daily ftorafur schedule over conventional 5-FU infusions.
为了用呋喃氟尿嘧啶替代繁重的5-氟尿嘧啶（5-FU）输注治疗，52例未经治疗的患者被随机分组，分别接受呋喃氟尿嘧啶联合丝裂霉素C或甲环亚硝脲治疗。呋喃氟尿嘧啶每月进行一次，每日2小时输注，共5天。丝裂霉素C和甲环亚硝脲每8周重复使用一次。丝裂霉素C组的缓解率为27%（26例患者中有7例缓解），而甲环亚硝脲组的缓解率为15%（26例患者中有4例缓解）（P = 0.25）。各治疗组之间的中位生存期无显著差异。超过30%的患者出现中枢神经系统毒性，这似乎是呋喃氟尿嘧啶给药的限制因素。由于每日使用呋喃氟尿嘧啶方案相较于传统的5-FU输注似乎没有什么优势，因此应探索呋喃氟尿嘧啶的其他给药方案。
